Protocol No. 20180146 entitled "A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Amgen, Inc.
Start Date
October 8, 2020
End Date
September 25, 2025
Administered By
Duke Cancer Institute
Awarded By
Amgen, Inc.
Start Date
October 8, 2020
End Date
September 25, 2025